市場調査レポート

商品コード

1619161

ヘモグロビン異常症治療市場規模、シェア、成長分析、タイプ別、治療タイプ別、最終用途別、地域別 - 産業別予測、2024～2031年

Hemoglobinopathies Treatment Market Size, Share, Growth Analysis, By Type (Sickle Cell Disease, Thalassemia), By Treatment Type (Blood Transfusion, Iron Chelation Therapy), By End-Use, By Region - Industry Forecast 2024-2031

出版日: 2024年12月18日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 817,578円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 956,412円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,095,246円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=154.26円

全表示
概要
目次

概要

サンプル依頼リストに入れる

ヘモグロビン異常症治療の世界市場規模は、2022年に82億8,000万米ドルと評価され、2023年の93億2,000万米ドルから2031年には240億9,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは12.6%で成長する見通しです。

世界のヘモグロビン異常症治療市場は、鎌状赤血球症やサラセミアなどの疾患に対する治療ソリューションの進歩により、力強い成長を遂げています。ヘモグロビン産生における遺伝子異常を特徴とするこれらの疾患は、遺伝子異常の修正と患者の予後改善を目的とした遺伝子治療、幹細胞移植、新薬治療などの技術革新に拍車をかけています。研究開発努力の増加と戦略的パートナーシップにより、新規治療法の導入が加速しています。さらに、新興市場における意識の高まり、政府の支援策、ヘルスケアインフラの充実も市場拡大に寄与しています。しかし、一部の地域では治療費の高騰や先進治療へのアクセスの制限といった課題があり、進展の妨げになる可能性があります。全体として、市場は患者のニーズを満たす個別化医療に重点を置きながら、大きな成長を遂げようとしています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場の最近の動向
企業の市場シェア分析（2023年）
主要企業の企業プロファイル
- 会社概要
- 製品ポートフォリオ分析
- セグメント別シェア分析
- 収益の前年比比較（2021-2023）

主要企業プロファイル

Sanofi S.A.（France）
Global Blood Therapeutics, Inc.（USA）
bluebird bio, Inc.（USA）
Emmaus Life Sciences, Inc.（USA）
Gamida Cell（Israel）
Pfizer, Inc.（USA）
Sangamo Therapeutics, Inc.（USA）
CRISPR Therapeutics（Switzerland）
Vertex Pharmaceuticals（USA）
Novartis AG（Switzerland）
Celgene Corporation（USA）
Editas Medicine（USA）
Bioverativ（USA）
Protagonist Therapeutics（USA）
F. Hoffmann-La Roche AG（Switzerland）
Bristol-Myers Squibb（USA）
Alnylam Pharmaceuticals（USA）
Ionis Pharmaceuticals（USA）
Silence Therapeutics（UK）

結論と推奨事項

Product Code: SQMIG35H2230

Global Hemoglobinopathies Treatment Market size was valued at USD 8.28 billion in 2022 and is poised to grow from USD 9.32 billion in 2023 to USD 24.09 billion by 2031, growing at a CAGR of 12.6% during the forecast period (2024-2031).

The global hemoglobinopathies treatment market is experiencing robust growth, driven by advancements in therapeutic solutions for conditions like sickle cell disease and thalassemia. Characterized by genetic abnormalities in hemoglobin production, these disorders have spurred innovations such as gene therapy, stem cell transplantation, and new drug therapies, aimed at correcting genetic defects and improving patient outcomes. Increasing research and development efforts, along with strategic partnerships, are accelerating the introduction of novel treatments. Additionally, heightened awareness, supportive government initiatives, and enhanced healthcare infrastructure in emerging markets contribute to market expansion. However, challenges like high treatment costs and limited access to advanced therapies in certain regions may hinder progress. Overall, the market is set for significant growth, focusing on personalized medicine to meet patient needs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hemoglobinopathies Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hemoglobinopathies Treatment Market Segmental Analysis

Global Hemoglobinopathies Treatment Market is segmented by type, treatment type, end-use and region. Based on type, the market is segmented into sickle cell disease, thalassemia and other hemoglobinopathies. Based on treatment type, the market is segmented into blood transfusion, iron chelation therapy, bone marrow transplantation, gene therapy and pharmacotherapy. Based on end-use, the market is segmented into hospitals, specialty clinics, ambulatory surgical centers and research and academic institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hemoglobinopathies Treatment Market

A significant driver of the global hemoglobinopathies treatment market is the growing emphasis on personalized medicine. This approach focuses on customizing treatment plans according to individual patient traits such as genetic profiles, disease severity, and therapeutic responses. Improvements in genetic testing and molecular diagnostics empower healthcare professionals to gain insights into the specific genetic mutations associated with hemoglobinopathies. Consequently, this understanding fosters the creation of targeted therapies and precision medicine strategies that enhance patient outcomes and satisfaction. The shift toward personalized medicine not only increases the effectiveness of existing treatments but also catalyzes the innovation of new therapeutic options tailored to individual needs.

Restraints in the Global Hemoglobinopathies Treatment Market

One of the significant challenges facing the global hemoglobinopathies treatment market is the exorbitant cost associated with advanced therapies. Innovative treatment options, including gene therapy and stem cell transplantation, require intricate procedures, specialized technology, and comprehensive post-treatment care, all of which escalate expenses considerably. This financial burden presents difficulties for both patients and healthcare systems, particularly in areas with limited medical resources and lower-income demographics. As a result, the high costs may restrict the adoption of these cutting-edge therapies, potentially creating inequities in healthcare delivery and outcomes for individuals suffering from hemoglobinopathies. Overcoming this financial barrier is essential to guarantee that all patients have access to effective treatment options.

Market Trends of the Global Hemoglobinopathies Treatment Market

The global hemoglobinopathies treatment market is witnessing a significant trend driven by the increasing focus on gene therapy as a revolutionary treatment modality. This trend is fueled by advancements in genetic engineering technologies, particularly CRISPR/Cas9, which facilitate precise correction of genetic mutations responsible for disorders such as sickle cell disease and thalassemia. As researchers and pharmaceutical companies intensify their efforts in R&D, numerous successful clinical trials and regulatory approvals are bolstering confidence in gene therapy's potential to rectify the underlying causes of these conditions. This shift towards innovative, targeted therapies positions gene therapy at the forefront of hemoglobinopathy treatment strategies, promising improved patient outcomes and a transformative impact on the market landscape.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2023
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Patent Analysis
Case Studies

Global Hemoglobinopathies Treatment Market Size by Type & CAGR (2024-2031)

Market Overview
Sickle Cell Disease
- Sickle Cell Anemia
- Sickle Hemoglobin-C Disease
- Sickle Beta-Thalassemia
Thalassemia
- Alpha Thalassemia
- Beta Thalassemia
Other Hemoglobinopathies

Global Hemoglobinopathies Treatment Market Size by Treatment Type & CAGR (2024-2031)

Market Overview
Blood Transfusion
Iron Chelation Therapy
Bone Marrow Transplantation
Gene Therapy
Pharmacotherapy
- Hydroxyurea
- L-Glutamine
- Voxelotor
- Crizanlizumab
- Other Drugs

Global Hemoglobinopathies Treatment Market Size by End-Use & CAGR (2024-2031)

Market Overview
Hospitals
Specialty Clinics
Ambulatory Surgical Centers
Research and Academic Institutes

Global Hemoglobinopathies Treatment Market Size & CAGR (2024-2031)

North America (Type, Treatment Type, End-Use)
- USA
- Canada
Europe (Type, Treatment Type, End-Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Treatment Type, End-Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Treatment Type, End-Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Treatment Type, End-Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2023
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Global Blood Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bluebird bio, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emmaus Life Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gamida Cell (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sangamo Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CRISPR Therapeutics (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Editas Medicine (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioverativ (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Protagonist Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alnylam Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ionis Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Silence Therapeutics (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

ヘモグロビン異常症治療市場規模、シェア、成長分析、タイプ別、治療タイプ別、最終用途別、地域別 - 産業別予測、2024～2031年

Hemoglobinopathies Treatment Market Size, Share, Growth Analysis, By Type (Sickle Cell Disease, Thalassemia), By Treatment Type (Blood Transfusion, Iron Chelation Therapy), By End-Use, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

ヘモグロビン異常症治療市場規模：タイプ別

ヘモグロビン異常症治療市場規模：治療タイプ別

ヘモグロビン異常症治療市場規模：最終用途別

ヘモグロビン異常症治療市場規模：地域別